STAT3 is frequently found to be constitutively activated in a wide range of cancers, including breast cancer, lung cancer, and melanoma. This persistent activation promotes oncogenic processes such as cell proliferation, survival, angiogenesis, and immune evasion. Therefore, targeting STAT3 offers a potential therapeutic strategy to inhibit these cancer-promoting pathways.
